GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Capex-to-Revenue

ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) Capex-to-Revenue : -0.03 (As of Jan. 2024)


View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

ImmunoPrecise Antibodies's Capital Expenditure for the three months ended in Jan. 2024 was $0.12 Mil. Its Revenue for the three months ended in Jan. 2024 was $4.64 Mil.

Hence, ImmunoPrecise Antibodies's Capex-to-Revenue for the three months ended in Jan. 2024 was -0.03.


ImmunoPrecise Antibodies Capex-to-Revenue Historical Data

The historical data trend for ImmunoPrecise Antibodies's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Capex-to-Revenue Chart

ImmunoPrecise Antibodies Annual Data
Trend Dec13 Dec14 Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.04 0.08 0.07 0.07

ImmunoPrecise Antibodies Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.08 0.02 0.05 -0.03

Competitive Comparison of ImmunoPrecise Antibodies's Capex-to-Revenue

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoPrecise Antibodies's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Capex-to-Revenue falls into.



ImmunoPrecise Antibodies Capex-to-Revenue Calculation

ImmunoPrecise Antibodies's Capex-to-Revenue for the fiscal year that ended in Apr. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.109) / 15.326
=0.07

ImmunoPrecise Antibodies's Capex-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0.123) / 4.635
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunoPrecise Antibodies  (NAS:IPA) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


ImmunoPrecise Antibodies Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) Business Description

Traded in Other Exchanges
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from Europe.